Harmonic Ratio in Patients With GLUT1 Deficiency Syndrome
Key facts
- Who runs it
- IRCCS National Neurological Institute "C. Mondino" Foundation
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 32 people enrolled
- Started
- 1 Jan 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Inertial gait analysis
- Record updated
- 30 April 2024
Who can take part
- Age
- 3 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Pediatric and adult patients (range 3-60 years) diagnosed with GLUT1 deficiency syndrome according to the recommendations of the International Study Group (Klepper et al., 2020)
- Ability to walk independently the necessary route
- Compliance with study procedures
- Typically developing healthy volunteers
- Age range 3-60 years
Who cannot take part
- Presence of other neurological or orthopedic comorbidities that may influence gait assessment
- Poor compliance with study procedures; Healthy controls eligibility criteria:
- Presence of neurological or orthopedic comorbidities that may influence gait assessment
Other criteria
- Patients eligibility criteria
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Glucose transporter deficiency syndrome type 1 (GLUT1DS) is a rare, genetically determined, neurometabolic disorder .
Read full original descriptionShow less
It is estimated that about 90% of affected patients present various pathological gait patterns. Ataxic, spastic, ataxo-spastic, or dystonic walking are the main manifestations described to date.
The kinematic gait analysis with inertial sensors represents a method that is easily applicable in clinical practice, with possible application in numerous neurological syndromes of the pediatric and adult age.
Through the kinematic gait analysis, it will be possible to obtain an accurate characterization of the gait of patients with GLUT1DS. This will allow, in the first place, a better knowledge of locomotor parameters in this rare cohort of patients. Given that kinematic analysis through a wearable sensor is a method that can be easily integrated into daily clinical practice, the data obtained could become prognostic biomarkers and significant outcome measures of the disease (also in relation to possible improvements deriving from treatment with a ketogenic diet or in the context of future pharmacological trials).
The 2 groups in the trial
- GLUT1DS
Patients affected by GLUT1 deficiency syndrome
Treatment: Inertial gait analysis
- Healthy controls
Age and sex matched healthy controls
Treatment: Inertial gait analysis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 April 2024